Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,128 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with hormone receptor-positive/HER2-negative breast cancer.
Brezden-Masley C, Fathers KE, Coombes ME, Pourmirza B, Xue C, Jerzak KJ. Brezden-Masley C, et al. Among authors: xue c. Breast Cancer Res Treat. 2021 Jan;185(2):507-515. doi: 10.1007/s10549-020-05960-4. Epub 2020 Oct 16. Breast Cancer Res Treat. 2021. PMID: 33064230 Free PMC article.
Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study.
Hurvitz SA, Bardia A, Quiroga V, Park YH, Blancas I, Alonso-Romero JL, Vasiliev A, Adamchuk H, Salgado M, Yardley DA, Berzoy O, Zamora-Auñón P, Chan D, Spera G, Xue C, Ferreira E, Badovinac Crnjevic T, Pérez-Moreno PD, López-Valverde V, Steinseifer J, Fernando TM, Moore HM, Fasching PA; coopERA Breast Cancer study group. Hurvitz SA, et al. Among authors: xue c. Lancet Oncol. 2023 Sep;24(9):1029-1041. doi: 10.1016/S1470-2045(23)00268-1. Lancet Oncol. 2023. PMID: 37657462 Free article. Clinical Trial.
Brief Report: Updated Efficacy and Safety Data From an Integrated Analysis of Entrectinib in Locally Advanced/Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
Fan Y, Drilon A, Chiu CH, Loong HHF, Siena S, Krzakowski M, Dziadziuszko R, Zeuner H, Xue C, Krebs MG. Fan Y, et al. Among authors: xue c. Clin Lung Cancer. 2024 Mar;25(2):e81-e86.e4. doi: 10.1016/j.cllc.2023.12.001. Epub 2023 Dec 7. Clin Lung Cancer. 2024. PMID: 38245456 Free article. No abstract available.
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study.
Ascierto PA, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S, Pereira RP, Eigentler T, Rutkowski P, Demidov L, Zhukova N, Schachter J, Yan Y, Caro I, Hertig C, Xue C, Kusters L, McArthur GA, Gutzmer R. Ascierto PA, et al. Among authors: xue c. Lancet Oncol. 2023 Jan;24(1):33-44. doi: 10.1016/S1470-2045(22)00687-8. Epub 2022 Nov 29. Lancet Oncol. 2023. PMID: 36460017 Clinical Trial.
De novo transcriptome assembly database for 100 tissues from each of seven species of domestic herbivore.
Wang Y, Huang Y, Zhen Y, Wang J, Wang L, Chen N, Wu F, Zhang L, Shen Y, Bi C, Li S, Pool K, Blache D, Maloney SK, Liu D, Yang Z, Li C, Yu X, Zhang Z, Chen Y, Xue C, Gu Y, Huang W, Yan L, Wei W, Wang Y, Zhang J, Zhang Y, Sun Y, Wang S, Zhao X, Luo C, Wang H, Ding L, Yang QY, Zhou P, Wang M. Wang Y, et al. Among authors: xue c. Sci Data. 2024 May 11;11(1):488. doi: 10.1038/s41597-024-03338-5. Sci Data. 2024. PMID: 38734729 Free PMC article.
4,128 results